Affiliations 

  • 1 Department of Internal Medicine and Cardiology, Charité-Universitätsmedizin Berlin, Campus Virchow, Berlin, Germany
  • 2 University Malaya Medical Centre, Kuala Lumpur, Malaysia
  • 3 University Hospital Královské Vinohrady Prague, Czech Republic
  • 4 IKEM Prague, Czech Republic
  • 5 SÚSCCH, a.s. Banská Bystrica, Slovak Republic
  • 6 Hospital General Universitario de Ciudad Real, Ciudad Real, Spain
  • 7 Hospital Universitario de Cruces, Bilbao, Spain
  • 8 Hospital Universitari Vall d'Hebron Barcelona, Spain
  • 9 Medical Scientific Affairs, B.Braun France, Saint-Cloud, France
  • 10 Hospital Universitari Germans Trias i Pujol, Badalona, Spain
  • 11 Chonnam National University, Gwangju, South Korea
  • 12 Daegu Fatima Hospital, Daegu, South Korea
  • 13 Kangdong Sacred Heart Hospital, Kangdong, South Korea
  • 14 Clinique du Millénaire, Montpellier, France
  • 15 Clinique Turin, Paris, France
  • 16 Hôpital Albert Schweitzer Colmar, France
  • 17 Centre Hospitalier d'Avignon, Avignon, France
  • 18 Städtische Kliniken Esslingen, Esslingen, Germany
  • 19 Gachon University Gil Medical Center, Incheon, South Korea
PLoS One, 2020;15(1):e0226606.
PMID: 31929543 DOI: 10.1371/journal.pone.0226606

Abstract

BACKGROUND: The objective of this study was to assess regional and ethnic differences in an unselected patient population treated with polymer-free sirolimus-eluting stents (PF-SES) in Asia and Europe.

METHODS: Two all-comers observational studies based on the same protocol (ClinicalTrials.gov Identifiers: NCT02629575 and NCT02905214) were combined for data analysis to assure sufficient statistical power. The primary endpoint was the accumulated target lesion revascularization (TLR) rate at 9-12 months.

RESULTS: Of the total population of 7243 patients, 44.0% (3186) were recruited in the Mediterranean region and 32.0% (2317) in central Europe. The most prominent Asian region was South Korea (17.6%, 1274) followed by Malaysia (5.7%, 413). Major cardiovascular risk factors varied significantly across regions. The overall rates for accumulated TLR and MACE were low with 2.2% (140/6374) and 4.4% (279/6374), respectively. In ACS patients, there were no differences in terms of MACE, TLR, MI and accumulated mortality between the investigated regions. Moreover, dual antiplatelet therapy (DAPT) regimens were substantially longer in Asian countries even in patients with stable coronary artery disease as compared to those in Europe.

CONCLUSIONS: PF-SES angioplasty is associated with low clinical event rates in all regions. Further reductions in clinical event rates seem to be associated with longer DAPT regimens.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.